Abstract
OVE26 mice are a widely used transgenic model of early-onset type 1 diabetes. These mice overexpress calmodulin in their pancreatic β cells, develop severe diabetes within the first weeks of life, and progress to severe diabetic complications including diabetic nephropathy and diabetic cardiomyopathy (DCM). To date, diabetic nephropathy in OVE26 mice has been well explored, leaving the progression of DCM and the gender impact in this type 1 diabetes model still unrevealed. In our study, male and female OVE26 mice and age-matched nondiabetic FVB mice were examined at 4, 12, 24, and 36 weeks for their cardiac function, body weight, blood glucose, and heart weight/tibia length ratio. Further, histopathological examination and Western blot analysis for the key markers demonstrate that DCM appears at 24 weeks OVE26 mice, initiating with cardiac senescence, followed by fibrosis and then cardiac dysfunction. Mitochondrial respiration function analysis showed no indication of dysfunction in OVE26 mice at 24 weeks of age in both genders. In addition, no significant difference for the pathogenic progression was observed between OVE26 and FVB mice in both males and females. In conclusion, this study suggests cardiac senescence and fibrosi...Continue Reading
References
Nov 8, 1972·The American Journal of Cardiology·S RublerA Grishman
Jun 27, 2000·Diabetes·A JagerC D Stehouwer
Feb 20, 2002·European Journal of Clinical Investigation·A BeckerC D A Stehouwer
Sep 6, 2002·Cardiovascular Toxicology·R A BrownJ Ren
Feb 28, 2003·Diabetes·Gang YePaul N Epstein
Oct 19, 2006·Journal of the American College of Cardiology·Lu CaiY James Kang
Aug 2, 2007·Nature Reviews. Molecular Cell Biology·Judith Campisi, Fabrizio d'Adda di Fagagna
Jul 18, 2008·Journal of the American Society of Nephrology : JASN·Shirong ZhengPaul N Epstein
Jul 29, 2008·Journal of Molecular and Cellular Cardiology·Jane ChiuSubrata Chakrabarti
Aug 30, 2008·The American Journal of Medicine·Ashish AnejaMichael E Farkouh
Dec 5, 2008·PLoS Biology·Jean-Philippe CoppéJudith Campisi
Jan 10, 2009·Nature Reviews. Cancer·Thomas Kuilman, Daniel S Peeper
Sep 17, 2009·Current Pharmaceutical Design·Mónica De la Fuente, Jaime Miquel
Jan 19, 2010·Annual Review of Pathology·Jean-Philippe CoppéJudith Campisi
Jul 28, 2012·Seminars in Nephrology·Maggie K Diamond-StanicKumar Sharma
Mar 2, 2013·Current Pharmaceutical Design·Sihem Boudina
Jun 12, 2013·Cell·Carlos López-OtínGuido Kroemer
Nov 20, 2013·Redox Biology·Edwin HoGemma A Figtree
Jan 31, 2014·Diabetologia·Heiko Bugger, E Dale Abel
Mar 25, 2014·Toxicology and Applied Pharmacology·Xia YinLu Cai
Aug 13, 2014·Circulation·Sarah D de FerrantiRobert H Eckel
Aug 22, 2014·BioMed Research International·Junzhen WuTao Sun
May 15, 2015·Journal of Diabetes Research·J Fuentes-AntrásÓ Lorenzo
Mar 17, 2017·GeroScience·Cesar A MeschiariMerry L Lindsey
Mar 21, 2017·Clinical and Experimental Pharmacology & Physiology·Lu LuBing Hui Wang
May 24, 2017·Clinical Science·Zheng XuLu Cai
Aug 5, 2017·Diabetologia·Guanghong JiaJames R Sowers
Dec 21, 2017·Scientific Reports·Kelly Lum-NaiheLakshmi Pulakat
Mar 13, 2018·Frontiers in Genetics·Adam D HudginsYousin Suh
Mar 21, 2018·Frontiers in Cardiovascular Medicine·Goro KatsuumiTohru Minamino
Jul 5, 2019·Journal of Cellular and Molecular Medicine·Jiqun WangLu Cai
Oct 30, 2019·International Journal of Molecular Sciences·Kana Tominaga, Hiroshi I Suzuki
Nov 5, 2019·Biochimica Et Biophysica Acta. Molecular Basis of Disease·Wanning WangYi Tan